Genovis Q3 2023: Sales in line but beat on EBIT, merger announced by Genovis partner Selecta Biosciences - Redeye

Redeye see a Q3 report from Genovis that came in just above our estimates in terms of sales but delivered a solid beat on the EBIT level. The enzyme business continues to show encouraging growth on the back of increasing ADC-related volumes. We expect to make minor changes to our forecasts on the back of the report and also leave a short comment on Genovis' partner Selecta Biosciences which on Monday announced a merger.

Länk till analysen i sin helhet: https://www.redeye.se/research/959754/genovis-q3-2023-sales-in-line-but-beat-on-ebit-merger-announced-by-genovis-partner-selecta-biosciences?utm_source=finwire&utm_medium=RSS